Preview

Регионарное кровообращение и микроциркуляция

Расширенный поиск

Кардиотонические стероиды: основные эффекты, терапевтические подходы

https://doi.org/10.24884/1682-6655-2016-15-1-11-26

Полный текст:

Аннотация

На протяжении последних 50 лет многочисленные исследования были направлены на поиски предполагемого натрийуретического гормона, обладающего свойствами дигиталисподобных веществ. К сегодняшнему дню эндогенные кардиотонические стероиды идентифицированы в плазме человека, грызунов и амфибий, а несомненность роли в регуляуции водно-электролитного баланса доказана. Обнаружение повышенного уровня МБГ в плазме при различных патологических состояниях, таких как артериальная гипертензия, хроническая почечная недостаточность, преэклампсия и хроническая сердечная недостаточность, поспособствовало продвижению исследований в направлении изучения вовлечения МБГ в патогенез вышеперечисленных заболеваний, а также биосинтеза МБГ. Было продемонстрировано, что, помимо основного натрийуретического эффекта, МБГ обладает вазоконстрикторными и профибротическими свойствами. Изучение патофизиологической роли МБГ в развитии сердечно-сосудистых заболеваний подтолкнуло исследователей к рассмотрению МБГ в качестве терапевтической мишени. В качестве основных подходов к терапии рассмотрены иммунонейтрализация МБГ моноклональными антителами, а также антагонистическое взаимодействие антагонистов альдостерона и МБГ. Дальнейшее изучение и идентификация механизмов действия и синтеза КТС позволяет расширить горизонты современной терапии.

Об авторах

Ю. Н. Григорова
Северо-Западный федеральный медицинский исследовательский центр
Россия


А. Я. Багров
National Institute on Aging, National Institutes of Health, Baltimore, MD; Институт эволюционной физиологии и биохимии им. И.М. Сеченова
Россия


О. В. Федорова
National Institute on Aging, National Institutes of Health, Baltimore, MD
Россия


Список литературы

1. Adair C. D., Buckalew V, Taylor K. et al. Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin binding immunoglobulin // Am. J. Nephrol. 1996. № 16. Р. 529-531.

2. Adair C. D., Luper A., Rose J. C. et al. The hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe preeclampsia: a double-blind, randomized, clinical trial // J. Perinatol. 2009. № 29. Р. 284-289.

3. Amin M. S., Reza E., Wang H. Sodium transport in the choroidplexus and salt-sensitive hypertension // Hypertension. 2009. № 54. Р. 860-867.

4. Amin M. S., Wang H. W., Reza E. et al. Distribution of epithelial sodium channels and mineralocorticoid receptors in cardiovascular regulatory centers in rat brain // Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005. № 289. Р. R1787-R1797.

5. Anderson D. E. , Fedorova O. V., Morrell C. H. et al. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives // Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008. № 294. Р. R1248-R1254.

6. Bagrov A. Y., Agalakova N. I., Kashkin V. A., Fedorova O. V. Endogenous cardiotonic steroids and differential patterns of sodium pump inhibition in NaCl-loaded salt-sensitive and normotensive rats // Am. J. Hypertens. 2009. № 22. Р. 559-563.

7. Bagrov A. Y., Dmitrieva R. I., Fedorova O. V. et al. Endogenous marinobufagenin-like immunoreactive substance. A possible endogenous Na,K-ATPase inhibitor with vasoconstrictor activity // Am. J. Hypertens. 1996. № 9. Р. 982-990.

8. Bagrov A. Y., Fedorova O. V., Dmitrieva R. I. et al. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs // Cardiovasc. Res. 1996. № 31. Р. 296-305.

9. Bagrov A. Y., Shapiro J. I., Fedorova O. V. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets // Pharmacol. Rev. 2009. № 61. Р. 9-38.

10. Bianchi G., Tripodi G., Casari G. et al. Two point mutations within the adducin genes are involved in blood pressure variation // Proc. Natl. Acad. Sci USA. 1994. № 26. Р. 3999-4003.

11. Blanco G., Mercer R. W. Isozymes of the Na/K- ATPase: heterogeneity in structure, diversity in function // Am. J. Physiol. 1988. № 275. Р. F633-F650.

12. Blaustein M. P. Sodium ions, calcium ions, blood pressure regulation and hypertension: A reassessment and a hypothesis // Am. J. Physiol. 1977. № 232. Р. C167-C173.

13. Bricker N. S. On the pathogenesis of the uremic state. An exposition of the “Trade off Hypothesis” // N. Engl. J. Med. 1972. № 286. Р. 1093-1099.

14. Briones A. M., Xavier F. E., Arribas S. M. et al. Alterations in structure and mechanics of resistance arteries from ouabain-induced hypertensive rats // Am. J. Physiol. Heart Circ Physiol. 2006. № 291. Р. H193-H201.

15. Dahl L. K., Knudsen K. D., Iwai J. Humoral transmission of hypertension: Evidence from parabiosis // Circ. Res. 1969. № 24. Suppl. 5. Р. 21-33.

16. de Mendonga M., Grichois M. L., Pernollet M. G. et al. Antihypertensive effect of canrenone in a model where endogenous ouabain-like factors are present // J. Cardiovasc. Pharmacol. 1988. № 11. Р. 75-83.

17. DeWardener H. E., Clarkson E. M. Concept of natriuretic hormone // Physiol Rev. 1985. № 65. Р. 658-759.

18. Dmitrieva R. I., Bagrov A. Y., Lalli E. et al. Mammalian bufadienolide is synthesized from cholesterol in the adrenal cortex by a pathway that is independent of cholesterol side-chain cleavage // Hypertension. 2000. № 36. Р. 442-448.

19. Doris P A. Immunological evidence that the adrenal gland is a source of an endogenous digitalis-like factor // Endocrinology. 1988. № 123 (5). Р. 2440-2444.

20. Dostanic-Larson I., Lorenz J. N., Van Huysse J. W. et al. Physiological role ofthe a1- and a2-isoforms of the Na-K- ATPase and biological significance of their cardiac glycoside binding site // Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006. № 290. Р. R524-R528.

21. Dostanic-Larson I., Van Huysse J. W., Lorenz J. N., Lingrel J. B. The highly conserved cardiac glycoside binding site of Na,K-ATPase plays a role in blood pressure regulation // Proc. Natl. Acad. Sci. USA. 2005. № 102. Р. 15845-15850.

22. Efendiev R., Krmar R. T., Ogimoto G. et al. Hypertension-linked mutation in the adducin alpha-subunit leads to higher AP2-mu2 phosphorylation and impaired Na,K-ATPase trafficking in response to GPCR signals and intracellular sodium // Circ. Res. 1994. № 95. Р. 1100-1108.

23. Elkareh J., Kennedy D. J., Yashaswi B. et al. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy // Hypertension. 2007. № 49. Р. 215-224.

24. Elkareh J., Periyasamy S. M., Shidyak A. et al. Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy // Am. J. Physiol. Renal. Physiol. 2009. № 296. Р. F1219-F1226.

25. Fedorova L. V., Raju V., El-Okdi N. et al. The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition // Am. J. Physiol. Renal. Physiol. 2009. № 296. Р. F922-F934.

26. Fedorova O. V., Agalakova N. I., Morrell C. H. et al. ANP differentially modulates marinobufagenin-induced sodium pump inhibition in kidney and aorta // Hypertension. 2006. № 48. Р. 1160-1168.

27. Fedorova O. V., Agalakova N. I., Talan M. I. et al. Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl loaded Dahl-S rats // J. Hypertens. 2005. № 23. Р. 1515-1523.

28. Fedorova O. V., Anderson D. E., Lakatta E. G., Bagrov A. Y. Interaction of high sodium chloride intake and psychosocial stress on endogenous ligands of the sodium pump and blood pressure in normotensive rats // Am. J. Physiol. 2001. № 281. Р. R352-R358.

29. Fedorova O. V., Bagrov A. Y. Endogenous cardenolide and bufadienolides Na/K-ATPase inhibitors. How they work together in NaCl-sensitive hypertension // Front. Biosci. 2005. № 10. Р. 2250-2256.

30. Fedorova O. V., Bagrov A. Y. Inhibition of Na/K ATPase from rat aorta by two endogenous Na/K pump inhibitors, ouabain and marinobufagenin. Evidence of interaction with different alpha-subunit isoforms // Am. J. Hypertens. 1997. № 10. Р. 929-935.

31. Fedorova O. V., Doris P. A., Bagrov A. Y. Endogenous marinobufagenin-like factor in acute plasma volume expansion // Clin. Exp. Hypertens. 1998. № 20. Р. 581-591.

32. Fedorova O. V., Emelianov I. V., Bagrov K. A. et al. Marinobufagenin - induced vascular fibrosis is a likely target for mineralcorticoid antagonists // J. Hypertens. 2015. № 33. Р. 1602-1610.

33. Fedorova O. V., Kolodkin N. I., Agalakova N. I. et al. Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats // Hypertension. 2001. № 37. Р. 462-466.

34. Fedorova O. V., Kolodkin N. I., Agalakova N. I. et al. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intak // J. Hypertens. 2005. № 23. Р. 835-842.

35. Fedorova O. V., Lakatta E. G., Bagrov A. Y. Differential effects of acute NaCl loading on endogenous ouabain-like and marinobufagenin-like ligands of the sodium pump in Dahl hypertensive rats // Circulation. 2000. № 102. Р. 3009-3014.

36. Fedorova O. V., Simbirtsev A. S., Kolodkin N. I. et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K- ATPase inhibition in lowers blood pressure in NaCl-sensitive hypertension // J. Hypertens. 2008. № 26. Р. 2414-2425.

37. Fedorova O. V., Talan M. I., Agalakova N. I. et al. An endogenous ligand of alpha-1 sodium pump, marinobufagenin, is a novel mediator of sodium chloride dependent hypertension // Circulation. 2002. № 105. Р. 1122-1127.

38. Fedorova O. V., Tapilskaya N. I., Bzhelyansky A. M. et al. Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae // J. Hypertens. 2010. № 28. Р. 361-366.

39. Fedorova O. V., Zernetkina V. Z., Shilova V. Y. et al. Synthesis of an endogenous steroidal Na pump inhibitior marinobufagenin, implicated in human cardiovascular diseases, is initiated by CYP27A1 via bile acid pathway // Circ. Cardiovasc. Genet. 2015. № 8(5). P. 736-745.

40. Fedorova O. V., Zhuravin I. A., Agalakova N. I. et al. Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor // J. Hypertens. 2007. № 25. Р. 18341844.

41. Ferrandi M., Molinari I., Barassi P et al. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238 // J. Biol. Chem. 2004. № 279. Р. 33306-33314.

42. Ferrari P., Ferrandi M., Tripodi G. et al. PST2238: a new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension // J. Pharmacol. Exp. Ther. 1999. № 288. Р. 1074-1083.

43. Finotti P., Palatini P Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase // J. Pharmacol. Exp. Ther. 1981. № 217. Р. 784-790.

44. Flier J. S., Edwards M. W., Daly J. W., Myers C. W. Widespread occurrence in frogs and toads of skin compounds interacting with the ouabain site of Na,K-ATPase // Science. 1980. № 208. Р. 503-505.

45. Flier J. S., Maratos-Flier E., Pallota J. A., McIsaac D. Endogenous digitalis-like activity in the plasma of the toad Bufo marinus // Nature. 1979. № 279. Р. 341-343.

46. Folkow B. Physiological aspects of primary hypertension // Physiol Rev. 1992. № 62. Р. 347-504.

47. Franklin S. S., Gustin W. 4th, Wong N. D. M. N. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study // Circulation. 1997. № 96. Р. 308-315.

48. Fridman A. I., Matveev S. A., Agalakova N. I. et al. Marinobufagenin, an endogenous ligand of a-1 Na/K-ATPase, is a marker of congestive heartfailure severity // J. Hypertens. 2002. № 20. Р 1189-1194.

49. Gabor A., Leenen F. H. Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats // Am. J. Physio. Regul. Integr. Comp. Physiol. 2009. № 296. Р. R618-R630.

50. Gates P. E., Tanaka H., Hiatt W. R. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension // Hypertension. 2004. № 44. Р. 35-41.

51. Gonick H. C., Ding Y., Vaziri N. D. et al. Simultaneous measurement of marinobufagenin, ouabain and hypertension-associated protein in various disease state // Clin. Exp. Hypertens. 1998. № 20. Р. 617-627.

52. Goodlin R. C. Antidigoxin antibodies in eclampsia // N. Engl. J. Med. 1988. № 31. Р. 1097-1103.

53. Goto A., Yamada K., Ishii M. et al. Immunoreactivity of endogenous digitalislike factors // Biochem. Pharmacol. 1991. № 41. Р. 1261-1263.

54. Graves S. W., Brown B., Valdes R. An endogenous digoxin-like substance in patients with renal impairment // Ann. of Int. Med. 1983. № 99. Р. 604-608.

55. Graves S. W., Valdes R. Jr., Brown B. A. et al. Endogenous digoxin-immunoreactive substance in human pregnancies // J. Clin. Endocrinol. Metab. 1984. № 58 (4). Р. 748-751.

56. Grigorova Y. N., Juhasz O., Zernetkina V. et al. Aortic fibrosis, induced by high salt intake in the absence of hypertensive response, is reduced by a monoclonal antibody to marinobufagenin // Am. J. Hypertens. doi: 10.1093/ajh/hpv155.

57. Gruber K. A., Whitaker J. M., Buckalew V. M. Endogenous digitalis-like substance in plasma of volume-expanded dogs // Nature. 1980. № 287. Р. 743-745.

58. Haas M., Askari A., Xie Z. Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na+/K+-ATPase // J. Biol. Chem. 2000. № 275. Р. 27832-27837.

59. Haas M., Wang H., Tian J., Xie Z. Src-mediated inter-receptor cross-talk between the Na+/K+-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases // J. Biol. Chem. 2002. № 277. Р. 18694-18702.

60. Haddy F. J., Overbeck H. W. The role of humoral agents in volume expanded hypertension // Life Sci. 1976. № 19. Р. 935-947.

61. Haller S. T., Kennedy D. J., Shidyak A. et al. Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure // Am. J. Hypertens. 2012. № 25 (6). Р. 690-696.

62. Hamlyn J. M., Blaustein M. P., Bova S. et al. Identification and characterization of a ouabain-like compound from human plasma // Proc. Natl. Acad. Sci USA. 1991. № 88. Р. 6259-6563.

63. Hamlyn J. M., Manunta P Ouabain, digitalis-like factors and hypertension // J. Hypertens. Suppl. 1992. № 10. Р. S99-S111.

64. Hamlyn J. M., Ringel R., Schaeffer J. et al. A circulating inhibitor of (Na,K)ATPase associated with essential hypertension // Nature. 1982. № 300. Р. 650-652.

65. Hillyard S. D., Lu E., Gonick H. C. Further characterization of the natriuretic factor derivedfrom kidney tissue of volume-expanded rats. Effects on short-circuit current and sodium-potassium-adenosine triphosphatase activity // Circ. Res. 1976. № 38. Р. 250-255.

66. Hilton P J., White R. W., Lord G. A. et al. An inhibitor of the sodium pump obtainedfrom human placenta // Lancet. 1996. № 348. Р. 303-305.

67. Hout S. J., Pamnani M. B., Clough D. L. et al. The role of sodium intake, the Na+-K+ pump and a ouabainlike humoral agent in the genesis of reduced renal mass hypertension // Am. J. Nephrol. 1983. № 3. Р. 92-99.

68. Huang B. S., Leenen F. H. Both brain angiotensin II and "ouabain" contribute to sympathoexcitation and hypertension in Dahl S rats on high salt intake // Hypertension. 1998. № 32. Р. 1028-1033.

69. Huang B. S., Leenen F. H. H. Sympathoexcitatory and pressor responses to increased brain sodium and ouabain are mediated via brain ANGII // Am. J. Physiol. 1996. № 270. Р. H275-H280.

70. Huang B. S., Van Vliet B. N., Leenen F. H. Increases in CSF [Na+] precede the increases in blood pressure in Dahl S rats and SHR on a high-salt diet // Am. J. Physiol. Heart Circ. Physiol. 2004. № 287. Р. H1160-H1166.

71. Ishkaraeva-Yakovleva V. V., Fedorova O. V., Solodovnikova N. G. DigiFab interacts with endogenous cardiotonic steroids and reverses preeclampsia-induced Na/K- ATPase inhibition // Reprodactive Science. 2012. № 19 (12). Р. 1260-1267.

72. Iwai J., Knudsen K. D., Dahl L. K. et al. Genetic influence on the development of renal hypertension in parabiotic rats. Evidence for a humoral factor // J. Exp. Med. 1969. № 129. Р. 507-522.

73. Iyoda I., Takahashi H., Lee L. C. et al. Cardiovascular and sympathetic responses to ouabain injected into the hypothalamus in rats // Cardiovasc. Res. 1986. № 20. Р. 294-298.

74. Jablonski K. L., Fedorova O. V., Racine M. L. et al. Dietary sodium restriction and association with urinary marinobufagenin, blood pressure, and aortic stiffness // Clin. J. Am. Soc. Nephrol. 2013. № 8. Р. 1952-1959.

75. Javitt N. B. Bile acid synthesis from cholesterol: regulatory and auxilarry pathways // FASEB J. 1994. № 8. Р. 1308-1311.

76. Kaess B. M., Rong J., Larson M. G. M. N. Aortic stiffness, blood pressure progression, and incident hypertension // JAMA. 2012. № 308. Р. 875-881.

77. Katz A. L. Renal Na-K-ATPase: its role in tubular sodium and potassium transport // Am. J. Physiol. 1982. № 242 (3). Р. 207-219.

78. Kennedy D. J., Elkareh J., Shidyak A. et al. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse // Am. J. Physiol. Renal. Physiol. 2008. № 294. Р. F450-F454.

79. Kennedy D. J., Vetteth S., Periyasamy S. M. et al. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy // Hypertension. 2006. № 47. Р. 488-495.

80. Kieval R. S., Butler V. P., Derguini F. et al. Cellular electrophysiologic effects of vertebrate digitalis-like substances // J. Am. Coll. Cardiol. 1988. № 11. Р. 637-643.

81. Kojima I., Yoshihara S., Ogata E. Involvement of endogenous digitalis-like substance in genesis of deoxycorticosterone-salt hypertension // Life Sci. 1982. № 30. Р. 1775-1781.

82. Kolmakova E. V., Haller S. T., Kennedy D. J. et al. Endogenous cardiotonic steroids in chronic renal failure // Nephrol. Dial. Transplant. 2011. № 26. Р. 2912-2919.

83. Kometiani P., Li J., Gnudi L. et al. Multiple signal transduction pathways link Na+/K+-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases // J. Biol. Chem. 1998. № 273. Р. 15249-15256.

84. Komiyama Y., Dong X. H., Nishimura N. et al. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure // Clin. Biochem. 2005. № 38. Р. 36-45.

85. Kubo M., Czuwara-Ladykowska J., Moussa O. et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin // Am. J. Pathol. 2003. № 163. Р. 571-581.

86. Lakatta E. G., Levy D. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises. P I: Agingarteries: A "set up" for vascular disease // Circulation. 2003. № 107. Р. 139-146.

87. Lam G., Johnson D., Robinson C. et al. Procceding of XVI Congress of International Society for the Study of hypertension in pregnancy. Vol. 44. Washington DC, 2008. Antepartum administration of a digoxin immune Fab (Digibind®) improves renal function in patients with severe preeclampsia. Р. 60.

88. LaMarca H. L., Morris C. A., Pettit G. R. et al. Marinobufagenin impairs first trimester cytotrophoblast differentiation // Placenta. 2006. № 27. Р. 984-988.

89. Lee W. R., Ishikawa T., Umetani M. The interaction between metabolism, cancer and cardiovascular disease, connected by 27-hydroxycholesterol // Clin. Lipidol. 2014. № 9 (6). Р. 617-624.

90. Leenen F. H. H., Harmsen E., Yu H. Dietary sodium and central vs. peripheral ouabain-like activity in Dahl salt- sensitive vs. salt-resistant rats // Am. J. Physiol. 1994. № 267. Р. H1969-H1920.

91. Leenen F. H. H., Ruzicka M., Huang B. S. The brain and salt-sensitive hypertension // Curr. Hypertens. Rep. 2002. № 4. Р. 129-135.

92. Li J., Daly E., Campioli E. et al. De novo synthesis of steroids and oxysterols in adypocytes // J. Biol. Chem. 2014. № 289 (2). Р. 747-764.

93. Liang M., Tian J., Liu L. et al. Identification ofapool of non-pumping Na/K-ATPase // J. Biol. Chem. 2007. № 282. Р. 10585-10593.

94. Lichtstein D., Gati I., Babila T., Katz U. Effect of salt acclimation on digitalis-like compounds in the toad // Biochim. Biophys. Acta. 1991. № 1073. Р. 65-68.

95. Lichtstein D., Gati I., Samuelov S. et al. Identification of digitalis-like compounds in human cataractous lenses // Eur. J. Biochem. 1993. № 216. Р. 261-268.

96. Liu J., Kesiry R., Periyasamy S. M. et al. Ouabain induces endocytosis of plasmalemmal Na/K-ATPase in LLC- PK1 cells by a clathrin-dependent mechanism // Kidney Int. 2004. № 66. Р. 227-241.

97. Liu J., Liang M., Liu L. et al. Ouabain-induced endocytosis of the plasmalemmal Na/K-ATPase in LLC- PK1 cells requires caveolin-1 // Kidney Int. 2005. № 67. Р. 1844-1854.

98. Liu J., Periyasamy S. M., Gunning W. et al. Effects of cardiac glycosides on sodium pump expression and function in LLC-PK1 and MDCK cells // Kidney Int. 2002. № 62. Р. 2118-21125.

99. Liu J., Shapiro J. I. Regulation of sodium pump endocytosis by cardiotonic steroids: Molecular mechanisms and physiological implications // Pathophysiology. 2007. № 14. Р. 171-181.

100. Liu J., Tian J., Haas M. et al. Ouabain interaction with cardiac Na+/K+-ATPase initiates signal cascades independent of changes in intracellular Na+ and Ca2+ concentrations // J. Biol. Chem. 2000. № 275. Р. 27838-27844.

101. Liu L., Mohammadi K., Aynafshar B. et al. Role of caveolae in signal-transducing function of cardiac Na+/ K+-ATPase // Am. J. Physiol. Cell. Physiol. 2003. № 284. Р. C1550-C1560.

102. London G. M. Cardiovascular Disease in Chronic Renal Failure: Pathophysiologic Aspects // Semin Dial. 2003. № 16. Р. 85-94.

103. Lopatin D. A., Ailamazian E. K., Dmitrieva R. I. et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia // J. Hypertens. 1999. № 17. Р. 1179-1187.

104. Mall G., Huther W., Schneider J. et al. Diffuse intermyocardiocytic fibrosis in uraemic patients // Nephrol. Dial. Transplant. 1990. № 5 (1). Р. 39-44.

105. Manunta P., Maillard M., Tantardini C. et al. Relationships among endogenous ouabain, alpha-adducin polymorphisms and renal sodium handling in primary hypertension // J. Hypertens. 2008. № 26. Р. 914-920.

106. Manunta P., Messaggio E., Ballabeni C. et al. Salt Sensitivity Study Group of the Italian Society of Hypertension, Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension // Hypertension. 2001. № 38. Р. 198-203.

107. Mohammadi K., Kometiani P., Xie Z., Askari A. Role of protein kinase C in the signal pathways that link Na+/ K+-ATPase to ERK1/2 // J. Biol. Chem. 2001. № 276. Р. 42050-42056.

108. Murrell J. R., Randall J. D., Rosoff J. et al. Endogenous ouabain: upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal // Circulation. 2005. № 112(9). Р. 1301-1318.

109. Najjar S. S., Scuteri A., Shetty V. M. N. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic bloodpressure and of incident hypertension in the Baltimore Longitudinal Study of Aging // J. Am. Coll. Cardiol. 2008. № 51. Р. 1377-1383.

110. Naruse K., Naruse M., Tanabe A. et al. Does plasma immunoreactive ouabain originate from the adrenal gland? // Hypertension. 1994. № 20. Р. 617-627.

111. Nelson E. R., Wardell S. E., Jasper J. S. et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology // Science. 2013. № 342. Р. 1094-1098.

112. Nikitina E. R., Mikhailov A. V., Nikandrova E. S. et al. In preeclampsia emdogenous cartdiotonic steroids induces vascular fibrosis and impair relaxation of umbilical arteries // J. Hypertens. 2011. № 29 (4). Р. 769-776.

113. Nikitina E. R., Nikandrova E. S., Frolova E. V. et al. Endogenous digitalis and impairment of vasorelaxation in preeclampsia // Arterial Hypertension (in Russian). 2009. № 15. Р. 454-457.

114. Oda M., Kurosawa M., Numazawa S. et al. Determination of bufalin-like immunoreactivity in serum of humans and rats by time-resolved fluoroimmunoassay for using a monoclonal antibody // Life Sci. 2001. № 68. Р. 1107-1117.

115. Oliver W. J., Cohen E. L., Neel J. V. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a "No-salt" culture // Circulation. 1975. № 52. Р. 146-151.

116. Orlov S. N., Mongin A. A. Salt-sensing mechanisms in blood pressure regulation and hypertension // Am. J. Physiol. Heart Circ. Physiol. 2007. № 293. Р. H2039-H2053.

117. Orosz D. E., Hopfer U. Pathophysiological consequences of changes in the coupling ration of Na,K- ATPase for renal sodium reabsorption and its implications for hypertension // Hypertension. 1996. № 27. Р. 219-227.

118. Overbeck H. W., Pamnani M. B., Akera T. et al. Depressed function of a ouabain-sensitive sodium-potassium pump in blood vessels from renal hypertensive dogs // Circ. Res. 1976. № 38(6 Suppl 2). Р. 48-52.

119. Overlack A., Ruppert M., Kolloch R. M. N. Divergent hemodynamic and hormonal responses to varying salt intake in normotensive subjects // Hypertension. 1993. № 22. Р. 331-338.

120. Oweis S., Wu L., Kiela P R., Zhao H. et al. Cardiac glycoside downregulates NHE3 activity and expression in LLC-PK1 cells // Am. J. Physiol. Renal Physiol. 2006. № 290. Р. F997-F1008.

121. Payne A. H., Hales D. B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones // Endocr. Rev. 2004. № 25(6). Р. 947-970.

122. Periyasamy S. M., Chen J., Cooney D. et al. Effects of uremic serum on isolated cardiac myocyte calcium cycling and contractile function // Kidney Int. 2001. № 60. Р. 2367-2376.

123. Periyasamy S. M., Liu J., Tanta F. et al. Salt loading induces redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells // Kidney Int. 2005. № 67. Р. 1868-1877.

124. Pikuleva I. A. Cytochrome P450s and cholesterol homeostasis // Pharmacol. Ther. 2006. № 112 (3). Р. 761-773.

125. Priyadarshi S., Valentine B., Han C. et al. Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat // Kidney Int. 2003. № 63. Р. 17851790.

126. Puschett J. B., E. Agunanne, Uddin M. N. Marinobufagenin, resibufogenin and preeclampsia //Arterial Hypertension. 2010. № 1802 (12). Р. 1246-1253.

127. Schneider R., Wray V., Nimtz M. et al. Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump // J. Biol. Chem. 1998. № 273. Р. 784-792.

128. Seals D. R., Tanaka H., Clevenger C. M. et al. Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: Role of arterial stiffness // J. Am. Coll. Cardiol. 2001. № 38. Р. 506-513.

129. Semplicini A., Serena L., Valle R. et al. Ouabain-inhibiting activity of aldosterone antagonists // Steroids. 1995. № 60. Р. 110-113.

130. Sich B., Kirch U., Tepel M. et al. Pulse pressure correlates in humans with a proscillaridin-A immunoreactive compound // Hypertension. 1996. № 27. Р. 1073-1077.

131. Stella P, Manunta P, Mallamaci F. et al. Endogenous ouabain and cardiomyopathy in dialysis patients // J. Intern. Med. 2008. № 263. Р. 274-280.

132. Takahashi H., Iyoda I., Takeda K. et al. Centrally-induced vasopressor responses to ouabain are augmented in spontaneously hypertensive rats // Clin. Exp. Hypertens. 1984. № A6. Р. 1499-1515.

133. Takahashi H., Matsusawa M., Ikegaki I. et al. Brain renin-angiotensin system and the hypothalamic, digitalis-like Na,K-ATPase inhibitor in rats // Clin. Exp. Hypertens. 1988. № A10. Р. 1285-1287.

134. Tian J., Cai T., Yuan Z. et al. Binding of Src to Na+/ K+-ATPase forms a functional signaling complex // Mol. Biol. Cell. 2006. № 17. Р. 317-326.

135. Tian J., Liu J., Garlid K. D. et al. Involvement of mitogen-activated protein kinases and reactive oxygen species in the inotropic action of ouabain on cardiac myocytes. A potential role for mitochondrial K(ATP) channels // Mol. Cell. Biochem. 2003. № 242. Р. 181-187.

136. Tian J., Shidyak A., Periyasamy S. M. et al. Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin // Hypertension. 2009. № 54. Р. 1313-1320.

137. Torielli L., Tivodar S., Montella R. C. et al. alpha- Adducin mutations increase Na/Kpump activity in renal cells by affecting constitutive endocytosis: implications for tubular Na reabsorption // Am. J. Physiol. Renal Physiol. 2008. № 295. Р. F478-F487.

138. Trejter M., Hochol A., Tyczewska M. et al. Sex-related gene expression profiles in the adrenal cortex in the mature rat: Microarray analysis with emphasis on genes involved in steroidogenesis // Int. J. Mol. Med. 2015. № 35 (3). Р. 702-714.

139. Umetani M., Shaul P. W. 27-hydroxycholesterol: the first identified endogenous SERM // Trend. Endocrinol. Metab. 2011. № 22 (4). Р. 130-135.

140. Uno Y., Hosaka S., Yamazaki H. Identification and analysis of CYP7A1, CYP17A1, CYP20A1 and CYP51A1 in Cynomolgus Macaques // J. Vet Med Sci. 2014. № 76(12). Р. 1647-1650.

141. Wang H., HaasM., LiangM. et al. Ouabain assembles signaling cascades through the caveolar Na+/K+-ATPase // J. Biol. Chem. 2004. № 279. Р. 17250-17529.

142. Wang H., Leenen F. H. Brain sodium channels and central sodium-induced increases in brain ouabain-like compound and blood pressure // J. Hypertens. 2003. № 21. Р. 1519-1524.

143. Wang H., Leenen F. H. H. Brain sodium channels and central sodium-induced increases in brain ouabain-like compound and blood pressure // J. Hypertens. 2003. № 21. Р. 1519-1524.

144. Wang J. G., Staessen J. A., Messaggio E. et al. Salt, endogenous ouabain and blood pressure interactions in the general population // J. Hypertens. 2003. №21. Р. 1475-1481.

145. Weinberger M. H., Miller J. Z., Luft F. C. M. N. Definitions and characteristics of sodium sensitivity and blood pressure resistance // Hypertension. 1986. № 8. Р II127-II134.

146. Xie Z., Cai T. Na+-K+--ATPase-mediated signal transduction: from protein interaction to cellular function // Mol. Interv. 2003. № 3. Р. 157-168.

147. Yoshika M., Komiyama Y., Konishi M. et al. Novel digitalis-like factor, marinobufotoxin, isolated from cultured Y-1 cells, and its hypertensive effect in rats // Hypertension. 2007. № 49. Р. 209-214.

148. Zhang J., Lee M. Y., Cavalli M. et al. Sodium pump alpha2 subunits control myogenic tone and blood pressure in mice // J. Physiol. 2005. № 569. Р. 243-256.


Для цитирования:


Григорова Ю.Н., Багров А.Я., Федорова О.В. Кардиотонические стероиды: основные эффекты, терапевтические подходы. Регионарное кровообращение и микроциркуляция. 2016;15(1):11-26. https://doi.org/10.24884/1682-6655-2016-15-1-11-26

For citation:


Grigorova Y.N., Bagrov A.Y., Fedorova O.V. Cardiotonic steroids: main effects, therapeutic applications. Regional blood circulation and microcirculation. 2016;15(1):11-26. (In Russ.) https://doi.org/10.24884/1682-6655-2016-15-1-11-26

Просмотров: 200


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-6655 (Print)